U.S. markets closed
  • S&P 500

    +44.31 (+1.01%)
  • Dow 30

    +238.20 (+0.68%)
  • Nasdaq

    +152.39 (+1.04%)
  • Russell 2000

    +10.17 (+0.46%)
  • Crude Oil

    +0.26 (+0.36%)
  • Gold

    -3.30 (-0.18%)
  • Silver

    -0.14 (-0.56%)

    -0.0003 (-0.02%)
  • 10-Yr Bond

    +0.0210 (+1.66%)

    -0.0013 (-0.10%)

    +0.3950 (+0.36%)

    +894.20 (+2.65%)
  • CMC Crypto 200

    -7.40 (-0.93%)
  • FTSE 100

    +59.28 (+0.85%)
  • Nikkei 225

    +159.80 (+0.58%)

Is BridgeBio Pharma (BBIO) Stock a Buy For 2021?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020, the Baron Health Care Fund returned 17.1% (institutional shares). In comparison, the benchmark S&P 500 Index was up 12.15%, while the Russell 3000 Health Care Index was up 10.08%. You should check out Baron’s top 5 stock picks for investors to buy right now, which could be the biggest winners of 2021.

In the Q4 2020 Investor Letter, Baron Health Care Fund highlighted a few stocks and BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of them. BridgeBio Pharma Inc. (NASDAQ:BBIO) is a biotechnology company. In the last three months, BridgeBio Pharma Inc. (NASDAQ:BBIO) stock gained 48.9% and on February 16th it had a closing price of $64.98. Here is what Baron Health Care Fund said:

"BridgeBio Pharma, Inc. is a diversified biotechnology company running a novel decentralized model of drug development focused on genetic medicine. During the period held, shares increased on news that GlaxoSmithKline had floated a $4.6 billion takeover offer for Eidos Therapeutics, of which BridgeBio owns 60%. We retain conviction in BridgeBio based on four upcoming critical data readouts that we think will help drive share performance."

Countries With Highest Medical Research Spending
Countries With Highest Medical Research Spending


In January, we published an article revealing that BridgeBio Pharma Inc. (NASDAQ:BBIO) was one of the top 10 stock picks by billionaire Andreas Halvorsen.

In Q3 2020, the number of bullish hedge fund positions on BridgeBio Pharma Inc. (NASDAQ:BBIO) stock decreased by about 7% from the previous quarter (see the chart here), so a number of other hedge fund managers don't believe in BridgeBio's growth potential. Our calculations showed that BridgeBio Pharma Inc. (NASDAQ:BBIO) isn't ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 216% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 121 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds' poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Here you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

At Insider Monkey we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost real estate prices. So, we recommended this real estate stock to our monthly premium newsletter subscribers. We go through lists like the 15 best innovative stocks to buy to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website:

Disclosure: None. This article is originally published at Insider Monkey.